To determine the impact of fellow, resident, or medical student (MS) involvement on outcomes in patients undergoing permanent (125)I prostate seed implant.
The study population consisted of men with clinically localized low/intermediate-risk prostate cancer treated with low-dose-rate permanent interstitial brachytherapy.
Cases were stratified according to resident, fellow, MS, or attending involvement. Outcomes were compared using analysis of variance, logistic regression, and log rank tests.
A total of 291 patients were evaluated. Fellows, residents, and MS were involved in 47 (16. 2%), 231 (79. 4%), and 34 (11. 7%) cases, respectively. Thirteen (4. 4%) cases were completed by an attending physician alone. There was no difference in freedom from biochemical failure when comparing the resident, fellow, or attending alone groups (p = 0. 10). There was no difference in V100 (volume of the prostate receiving 100% of the prescription dose) outcomes when comparing resident cases to fellow cases (p = 0. 72) or attending alone cases (p = 0. 78). There was no difference in D90 (minimum dose covering 90% of the postimplant volume) outcomes when comparing resident cases to fellow cases (p = 0. 74) or attending alone cases (p = 0. 58). When examining treatment toxicity, fellow cases had higher rates of acute Grade 2 + GU toxicity (p = 0. 028). With the exception of higher urethra D90 among PGY 2-3 cases (p = 0. 02), dosimetric outcomes were similar to cases with PGY 4-5 resident participation. There was no difference in outcomes for cases with and without MS participation.
Interstitial prostate seed implants can be safely performed by trainees with appropriate supervision. Hands-on brachytherapy training is effective and feasible for trainees.
Brachytherapy. 2016 Jan 29 [Epub ahead of print]
Talha Shaikh, Lora Wang, Karen Ruth, Mark Hallman, David Y Chen, Richard E Greenberg, Jinsheng Li, Kevin Crawford, Eric M Horwitz
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA. , Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA. , Department of Biostatistics, Fox Chase Cancer Center, Philadelphia, PA. , Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA. , Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA. , Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA. , Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA. , Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA. , Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA.